Corvus Pharmaceuticals: Turnaround In Progress, Multiple Readouts Ahead
Performance is slightly negative since my July update piece (shares lost up to 60% of their value at one point). I provide a recap of the bullish thesis and management’s presentation at Credit Suisse Healthcare Conference. Adenosine gene expression signature is an intriguing biomarker to use for ciforadenant going forward (first in RCC, then …
News story posted on 2020-01-20T22:32:00.0000000Z
